Evidence map›Paper›PMID 26097582›Full record

ArticleInternational journal of clinical and experimental pathology2015

Large palpable ductal carcinoma in situ is Her-2 positive with high nuclear grade.

Ahmad Monabati, Ali-Reza Sokouti, Sadat Noori Noori, Akbar Safaei, Abd-Rasul Talei, Shapoor Omidvari, Negar Azarpira

Abstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Predictors for upstaging of ductal carcinomaMolecular and clinical oncology · 2020
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ahmad MonabatiDepartment of Pathology, Hematology Research Center, Shiraz University of Medical Sciences Shiraz, Iran.
Ali-Reza SokoutiDepartment of Pathology, Hematology Research Center, Shiraz University of Medical Sciences Shiraz, Iran.
Sadat Noori NooriDepartment of Pathology, Hematology Research Center, Shiraz University of Medical Sciences Shiraz, Iran.
Akbar SafaeiDepartment of Pathology, Hematology Research Center, Shiraz University of Medical Sciences Shiraz, Iran.
Abd-Rasul TaleiDepartment of Surgery, Shiraz University of Medical Sciences Shiraz, Iran.
Shapoor OmidvariDepartment of Radiotherapy, Shiraz University of Medical Sciences Shiraz, Iran.
Negar AzarpiraTransplant Research Center, Shiraz University of Medical Sciences Shiraz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ductal carcinoma in situ (DCIS) of the breast is a heterogeneous group with variable clinical presentation. The exact molecular mechanism is not known why some ductal carcinomas may reach to such a large size but still remains in situ. Although, molecular classification of DCIS lesions and nuclear grading are important for identification of more aggressive lesions but it is not sufficient. Our aim was to examine the expression pattern of immunohistochemical (IHC) markers of ER, PR, HER-2 in palpable DCIS lesions and compare with clinicopathological findings. Our center is referral hospital from South of Iran. Samples were obtained from fifty four patients with a diagnosis of palpable DCIS. Equivocal (2+) case in HER-2 IHC testing was more characterized by chromogenic in situ hybridization. The positive frequency of HER2, ER, and PR was 92%, 48%, and 37% respectively. Palpable DCIS lesions were significantly more HER-2 positive (92%). The DCIS cases were more likely to be of high nuclear grade (grade III) and Her-2 positive cases were more likely to be of high nuclear grade than intermediate grade. All ER negative tumors had high nuclear grade. The Her-2 positivity is suggested as the most important factor responsible for marked in situ proliferation and production of palpable mass.

Indexed as

AdultAgedBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedPalpationReceptors, EstrogenReceptors, ProgesteroneERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneDuctal carcinoma in situgradingHer-2palpable

Identifiers

PMID26097582
PMCPMC4466969

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.